A double-blind, randomized, dose-finding study to assess the efficacy of the gonadotrophin-releasing hormone antagonist ganirelix (Org 37462) to prevent premature luteinizing hormone surges in women undergoing ovarian stimulation with recombinant follicle stimulating hormone (Puregon®)

Human Reproduction

Volumn 13, Issue 11, 1998, Pages 3023-3031

  Mannaerts, B ^a  

^a NV ORGANON   (Netherlands)

Author keywords

GnRH antagonist ganirelix; IVF; LH surge prevention; Ovarian stimulation; Recombinant FSH

Indexed keywords

CHORIONIC GONADOTROPIN; ESTRADIOL; GANIRELIX; LUTEINIZING HORMONE; RECOMBINANT FOLLITROPIN; UNCLASSIFIED DRUG;

ADULT; ARTICLE; ASTHENIA; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOSE CALCULATION; DOSE RESPONSE; DOUBLE BLIND PROCEDURE; DRUG BLOOD LEVEL; DRUG SAFETY; DRUG TOLERABILITY; EDEMA; EMBRYO TRANSFER; ESTRADIOL BLOOD LEVEL; FEMALE; FEMALE INFERTILITY; HEMATOMA; HUMAN; INJECTION PAIN; LUTEINIZING HORMONE BLOOD LEVEL; LUTEINIZING HORMONE RELEASE; MAJOR CLINICAL STUDY; MALAISE; MENSTRUAL CYCLE; MULTICENTER STUDY; NAUSEA; NIDATION; OVULATION INDUCTION; PHASE 2 CLINICAL TRIAL; PREGNANCY RATE; PRURITUS; RANDOMIZED CONTROLLED TRIAL; SPONTANEOUS ABORTION; SUBCUTANEOUS DRUG ADMINISTRATION; TREATMENT OUTCOME;

EID: 3643130143     PISSN: 02681161     EISSN: None     Source Type: Journal    
DOI: 10.1093/humrep/13.11.3023     Document Type: Article

References (35)

1. Albano, C, Smitz, J., Camus, M. et al. (1996) Hormonal profile during the follicular phase in cycles stimulated with a combination of human menopausal gonadotrophin and gonadotropin-releasing hormone antagonist (cetrorelix) Hum. Reprod., 11, 2114-2118.
2. Albano, C., Smitz, J., Camus, M. et al. (1997) Comparison of different doses of gonadotrophin-releasing hormone antagonist cetrorelix during controlled ovarian hyperStimulation. Fertil. Steril., 67, 917-922.
3. Altman, D.G. and Bland, M.J. (1995) Statistics notes: absence of evidence is not evidence of absence. Er. Med. J., 311, 485.
4. Brus, L., Lambalk, C.B., de Koning J. et al. (1997) Specific gonadotrophinreleasing hormone analogue binding predominantly in human luteinized follicular aspirates and not in human pre-ovulatory follicles. Hum. Reprod., 12, 769-773.
5. Cassadenti, D.L., Sauer, M.V., Paulson R.J. et al. (1991) Comparison of intermittent and continuous use of a gonadotropin-releasing hormone antagonist (Nal-Glu) in in vitro fertilization cycles: a preliminary report. Am. J. Obstet. Gynecol., 165, 1806-1810.
6. Chang, J.Y. and Hsu, J.C. (1992) Optimal designs for multiple comparisons with best. J. Statist. Planning Inference, 30, 45-62.
7. Conn, P.M. and Crowley, W.F. (1994) Gonadotrophin-releasing hormone and its analogs. Annu. Rev. Med., 45, 391-405.
8. Couzinet, B., Lestrat, N., Brailly, S. et al. (1988) Stimulation of ovarian follicular maturation with pure follicle stimulating hormone in women with gonadotrophin deficiency. J. Clin. Endocrinol. Metab., 66, 552-556.
9. De long, D., Mackion, N.S., Mannaerts B. et al. (1998) High dose gonadotrophin-releasing hormone antagonist (ganirelix) may prevent ovarian hyperstimulation syndrome caused by ovarian stimulation for in-vitro fertilization. Hum. Reprod., 13, 573-575.
10. Devroey, P., Mannaerts, B., Smitz, J. et al. (1994) Clinical outcome of a pilot efficacy study on recombinant human FSH (Org 32489) combined with various GnRH agonist regimens. Hum. Reprod., 9, 1064-1069.
11. Diedrich, K., Diedrich, C., Santos, E. et al. (1994) Suppression of the endogenous luteinizing hormone surge by the gonadotrophin-releasing hormone antagonist cetrorelix during ovarian stimulation. Hum. Reprod., 9, 788-791.
12. Driessen, S.G.A.J. (1991) Multiple comparisons with and selection of the best treatment in (incomplete) block designs. Communications in Statistics Theory and Methods, 20, 179-218.
13. Dubourdieu, S., Charbonnel, B., d'Acremont, M. et al. (1994) Effect of administration of a gonadotrophin-releasing hormone (GnRH) antagonist (Nal-Glu) during the periovulatory period: the luteinizing hormone surge requires secretion of GnRH. J. Clin, Endocrinol Metab., 78, 343-347.
14. Felberbaum, R., Reissman, T.K., Kupker, W. et al. (1995) Preserved pituitary response under ovarian stimulation with HMG and GnRH-antagonists (Cetrorelix) in women with tubal infertility. Eur. J. Obstet. Gynecol. Reprod. Biol., 61, 151-155.
15. Felberbaum, R., Reissman, T.K., Kupker, W. et al. (1996) Hormone profiles and ovarian stimulation with hMG and concomitant administration of the GnRH-antagonist cetrorelix in different dosages. J. Assist. Reprod. Genet., 13,216-222.
16. Filicori, M., Santoro, N., Merriam, G.R. et al. (1986) Characterization of the physiological pattern of episodic gonadotropin secretion throughout the human menstrual cycle. J. Clin. Endocrinol. Metab., 62, 1136-1144.
17. Freeman, P.R. (1993) The role of p-values in analysing trial results. Stat. Med., 12, 1443-1452.
18. Frydman, R., Cornel, C., de Ziegler, D. et al. (1991) Prevention of premature luteinizing hormone and progesterone rise with a gonadotrophin-releasing hormone antagonist, Nal-Glu, in controlled ovarian hyperstimulation. Fertil. Steril., 56, 923-927.
19. Gordon, K., Danforth, D.R., Williams, R.F. et al. (1990) A novel regimen of gonadotrophin-releasing hormone (GnRH) antagonist plus pulsatile GnRH: controlled restoration of gonadotrophin secretion and ovulation induction. Fert. Steril., 54, 1140-1145.
20. Ikeda, M., Taga, M. Kurogi, K. and Minaguchi, H. (1997) Gene expression of gonadotrophin-releasing hormone, but not its receptor, in human endometrium and decidua. Mol. Endocrinol., 135, 165-168.
21. Itskovitz-Eldor, J., Kol, S., Mannaerts, B. and Coelingh Bennink, H. (1998) First established pregnancy after controlled ovarian hyperstimulation with recombinant follicle stimulating hormone and GnRH antagonist ganirelix (Org 37462). Hum. Reprod., 13, 294-295.
22. Karsch, F.J., Boweb, J.M., Caraty, A. et al. (1997) Gonadotrophin-releasing hormone requirements for ovulation. Biol. Reprod., 56, 303-309.
23. Latouche, J., Crumerolle-Arias, M., Jordan, D. et al. (1989) GnRH receptors in human granulosa cells: anatomical localization and characterization autoradiographic study. Endocrinology, 125, 1739-1741.
24. Minaretzis, D., Alper, M.M., Oskowitz, S.P. et al. (1995a) Gonadotrophinreleasing hormone antagonist versus agonist administration in women undergoing controlled ovarian hyperstimulation: cycle performance and in vitro steroidogenesis of granulosa-lutein cells. Am. J. Obstet. Gynecol., 172,1518-1525.
25. Minaretzis, D., Jakubowski, M., Mortola, J.F. et al. (1995b) Gonadotrophin releasing hormone receptor gene expression in human ovary and granulosa lutein cells. J. Clin. Endocrinol. Metab., 80, 430-433.
26. Nelson, L.R., Fujimoto, V.Y., Jaffe, R.B. et al. (1995) Suppression of follicula phase pituitary-gonadal function by a potent new gonadotrophin-releasing hormone antagonist with reduced histamine-releasing properties (ganirelix). Fert. Steril. 63, 963-969.
27. Nerenberg, C., LaFargue, J., Gee, C. et al (1993) Radioimmunoassay of ganirelix in plasma or serum. J. Immunoassay, 14, 191-207,
28. Olivennes, F., Fachin, R., Bouchard, P. et al. (1994) The single or dua administration of the gonadotrophin-releasing hormone antagonist cetrorelix in an in vitro fertilization-embryo transfer program. Fertil. Steril., 62, 468-476.
29. Olivennes, F., Fachin, R., Bouchard, P. et al. (1995) Scheduled administration of a gonadotrophin-releasing hormone antagonist (Cetrorelix) on day 8 of in-vitro fertilization cycles: a pilot study. Hum. Reprod., 10, 1382-1386.
30. Olivennes, K, Fachin, R., Bouchard, P. et al. (1996) Triggering of ovulation by a gonadotrophin-releasing hormone (GnRH) agonist in patients pretreated with a GnRH antagonist. Fertil. Steril, 66, 151-153.
31. Out, H.J., Mannaerts, B.M.J.L., Driessen, S.G.A.J. et al. (1995) A prospective randomised, assessor-blind, multicentre study comparing recombinant an urinary follicle stimulating hormone (Puregon versus Metrodin) in in-vitr fertilization. Hum. Reprod., 10, 2534-2540.
32. Pocock, S.J. (1997) Clinical trials with multiple outcomes: a statistical perspective on their design, analysis, and interpretation. Controlled Clinical Trials, 18, 530-549.
33. Rabinovici, J., Rothman, P., Monroe, S.E. et al. (1992) Endocrine effects and pharmacokinetic characteristics of a potent new gonadotrophin-releasing hormone antagonist (ganirelix) with minimal histamine-releasing properties studies in postmenopausal women. J. Clin. Endocrinol. Metab., 75, 1220-1225.
34. Schoot, D.C., Coelingh Bennink, H.J.T., Mannaerts, B.M.J.L. et al. (1992) Human recombinant follicle-stimulating hormone induces growth of preovulatory follicles without concomitant increase in androgen and estroge biosynthesis in a woman with isolated gonadotrophin deficiency. J. Clin. Endocrinol. Metab., 74, 1471-1473
35. Schoot, D.C., Harlin, J., Shoham, Z. et al. (1994) Recombinant human folliclestimulating hormone and ovarian response in gonadotrophin-deficient women. Hum. Reprod., 9, 1237-1242.